Formulation of Mupirocin Adsorbed Silver Nanoparticle with Antibiofilm Agents for Enhancing Antibacterial Activity

Selliamman Ravi Mahi Priya1, Rajandurai Baby Roselin1, Arjunan Karuppiah, Veintramuthu Sankar1,.*

Department of Pharmaceutics, PSG College of Pharmacy, Coimbatore, Tamil Nadu, INDIA.

ABSTRACT

Introduction: Biofilm is a complex structure of microbiome having different bacterial colonies or single type of cells in a group, adhere to the surface to produce infections. Nanoparticles (NPs) are widely used in different technological fields especially medicine because of their antibacterial properties. Silver nanoparticles (AgNPs) possess antimicrobial and antibiofilm property against various microbial infections. Objectives: The main objective of this study was to develop new formulations and characterization of mupirocin loaded silver nanoparticles with various anti biofilm agents. Methods: Silver nanoparticles formulations were prepared by tannic acid (TA) with trisodium citrate (TSC), Para-amino salicylic acid (PASA) and ascorbic acid (ASC) as both reducing and antibiofilm agents against Staphylococcus aureus followed by surface adsorption of Mupirocin (MUP). Transmission Electron Microscope (TEM) shows that the nanoparticles are roughly spherical in shape which was also confirmed by Atomic Force Microscopy (AFM). The particle size was in the range between 50 nm – 250 nm and found to be statistically significant (p<0.001) between the three AgNP formulations. In vitro drug release using the dialysis membrane showed a maximum release of 90% ± 2.343 in AgNPs (TSC TA) formulation at the end of 7 hr with the maximum drug entrapment of 93.75%. The formulations were tested for antimicrobial activity against S. aureus. The results were statistically compared using one way ANOVA and student t test. Conclusion: There is no significant difference in antibacterial activity between three AgNP formulations. However the best synergistic activity against planktonic S. aureus bacteria was shown by AgNP-PASA inspite of its minimal drug release when compared to AgNPs (TSC TA).

Key words: Staphylococcus aureus, Silver nanoparticles, Mupirocin, Surface adsorption, Antibiofilm.

INTRODUCTION

Globally, the bacterial resistance has highlighted an urgent need to battle the challenge of bacterial infection at wound sites. Antimicrobial resistance at the infected site is identified as a serious medical issue that increases morbidity as well as mortality.1 The micro-organisms can live in both the planktonic (free-living) and biofilm phenotypic states. They may play an important role in impairing healing and causing infection in both acute and chronic wounds.2 Antibiotics are preferred for the treatment of infections caused by these bacteria, because of the results achieved and their cost-effectiveness. Due to their inability of existing antibiotics to combat bacterial infections, there is a huge demand for unconventional biocides is intense. Nanotechnology is an emerging field with enormous scope, and nanomedicine provides an excellent platform for overcoming the problem of drug resistance.3 The conjugation of antimicrobial agents and nanoparticles (NPs) also improve the capabilities to kill microbial pathogens which are the primary cause for the development of antimicrobial resistance. Nanoformulations that contain antimicrobial agents also allow...
dosage reductions and improve their activities. Antibiotic-conjugated NPs enhance antibiotic concentrations in sites of the bacterium – antimicrobial interaction and aid the binding of antimicrobial agents to bacteria. Biofilm is a complex structure of microbiome having different bacterial colonies or a single type of cells in a group that adhere to the surface of the wound. The wound infections caused by biofilms are difficult to diagnose and treat. Biofilms have detrimental effects on wound healing by affecting healing times, risk of infection and costs to health service.

Mupirocin is an effective antibacterial agent often used in clinical practice as a topical ointment to treat a wide variety of topical wounds including burns and foot ulcers. The chemical structure consists of fatty acids that is loaded on monic acid by an ester-type linkage which mimics the carbon skeleton of isoleucine, competing with this amino acid for the active site of isoleucyltRNA bacterial synthetase, inhibiting bacterial protein synthesis.

Silver nanoparticles (AgNPs) are one of the most leading nanoproducts for medical purposes, due to their immense antimicrobial activity. The main feature of nanoparticles is their small size, which provides a larger contact surface with the bacterial cell, increasing its penetration and enhancing their bactericidal effect. This involves two distinct steps that will each have an impact on its efficiency. The first one is that the ability of the system to behave in the environment of interest, where physical or chemical changes can occur. Among these, aggregation, dissolution, Redox (photo) reactions, the release of adsorbed silver species, adsorption or desorption of ions, molecular species or polymers, or interaction with other nanoparticles or surfaces can modify the speciation of silver, thereby affecting this metal availability and influencing the antibacterial effect. The next step is the way through which the silver-containing species interact with the bacterial cell and eventually leads to cellular death.

Tannic acid is a natural and also a process derived phenolic compound that is a potent antagonist against bacteria. The mechanism of biofilm inhibition was found to be dependent on the putative transglycosylase IsaA. Salicylic acid which is the main aspirin metabolite exhibits various effects on the expression of S. aureus virulence factors. They also possess the ability to form complexes with iron cations and it has been proved that different iron-chelating molecules reduce the formation of biofilm. They also modify the activity of CodY, a metabolite – responsive global regulator, controls metabolism and virulence and gene expression through several molecular mechanisms. It represses ica and also cap gene transcripts in S. aureus. Ascorbic acid which is commonly known as Vitamin C can inhibit pathogenic bacteria and inhibit biofilms. They inhibit icaA dependent polysaccharide intracellular adhesion thereby inhibiting the interaction between cells. The investigation was undertaken to determine the antibacterial effect of antibiofilm agents with mupirocin loaded silver nanoparticles.

**MATERIALS AND METHODS**

**Materials**

Mupirocin was obtained as a gift sample from the Pharmaceutical Company, Foursite India Laboratories Pvt Ltd, Chennai. Silver nitrate and Sodium borohydride was purchased from Sigma Aldrich. Tannic acid, Para-amino salicylic acid, Ascorbic acid, Muller-Hinton Broth, Sodium hydroxide was obtained from Himedia Laboratories Pvt. Ltd., Bangalore.

**Methods**

**Preformulation studies**

The Digital melting point apparatus was used to determine the melting point of the drug by capillary tube method. The Lambda max of mupirocin in phosphate buffer 7.4 was scanned between 200-400 nm by UV-Visible spectrophotometer. The calibration curve was plotted for the solution in the order of increasing concentration.

**Silver nanoparticle synthesis**

**Silver nitrate reduced with sodium borohydride**

Excess sodium borohydride was needed to reduce the ionic silver and to stabilize the silver nanoparticles. Different volumes of 0.001M silver nitrate were added drop wise (about 1 drop per second) to 30ml of 0.002M sodium borohydride (NaBH₄) solution. This mixture was stirred on a magnetic stirrer. The solution will turn light yellow after the addition of 2ml of silver nitrate and then a bright yellow color develops when all of the silver nitrate has been added. The entire addition process took about 3 min and then the stirring was stopped. Reaction conditions like stirring time and quantities of reagents (both the absolute number of moles of reactant and their relative molarities) must be carefully controlled to obtain the stable yellow colloidal silver nanoparticles.

**Silver nitrate reduced with tannic acid**

For the preparation of silver nanoparticles, AgNO₃ solution and tri-sodium citrate were used as a metal salt precursor and a reducing agent. Tannic acid (TA) solution which is a primary antibiofilm agent act as an
auxiliary reductant and stabilizer. 10 ml of 6.8 mM aqueous solution of tannic acid was mixed with the tri-sodium citrate solution of different concentration and heated to 60°C using magnetic stirrer. This mixture was added to 50 ml of solution containing 8 mg of silver nitrate (AgNO₃) solution preheated to 60°C under vigorous stirring. The mixture was kept at 60°C for 30 min and boiled for 15 min respectively. The transparent colorless AgNO₃ solution mixture was converted to the characteristic pale yellow color after the addition of a required mixture of tri-sodium citrate and tannic acid solution. This color change denotes the formation of silver nanoparticle.

Silver nitrate reduced with Para- Amino salicylic acid (PASA)

Silver nitrate solution (0.3 × 10⁻³ mol/L) was added drop wise to pH- adjusted p-amino salicylic acid (10×10⁻³ mol/L) in a test tube with volume ratio of 1:1. The mixture was then slowly heated in a boiling water bath for few minutes until it turns yellow which implies the formation of AgNPs. The mixture was cooled under tap water and transferred to a small bottle for further analysis. For reaction optimization, some parameters were varied, such as pH (10-12), reaction time (5, 10, 15, 20, 25, 30 min).

Silver nitrate reduced with Ascorbic acid

Silver nitrate was used as a starting material while trisodium citrate and ascorbic acid were used as antibiofilm agent and reducing agent respectively. The concentration of trisodium citrate and ascorbic acid were varied to observe the effect of these parameters especially on the size and morphology of the silver nanoparticles. In detail, 80 ml of AgNO₃ was first heated to 60° and was then added (with vigorous stirring) to 20 ml of a trisodium citrate and ascorbic acid solution which was pre-heated to 60°. The mixture was then stirred for 20 min. After that, the heating was stopped and the solution was cooled to room temperature with continuous stirring. The solution will turn to brighter yellow/ brownish red when all of the silver nitrates had been added. During the formulation 1% of polyvinyl pyrrolidine was added as the capping agent at the end of the reaction. The spectrum peak widely ranging from 300 to 450 nm wave length indicates the formation of silver ions in the formulation.

Surface Adsorption of Mupirocin on AgNP

Mupirocin is adsorbed to AgNP surface by electrostatic interaction method. Mupirocin 40 mg was added to 40 ml of AgNP solution and stirred in a magnetic stirrer at room temperature for 24 hr. Lambda max and spectrum of the formulation after drug adsorption was determined by UV- double beam spectroscopy.

Evaluation of Mupirocin loaded Silver nanoparticles

The obtained mupirocin loaded silver nanoparticles were evaluated by their adsorption efficiency, in vitro drug release. Morphological characteristics were analyzed by Zeta sizer, Atomic Force Microscopy (AFM) and Transmission Electron Microscopy (TEM) studies. The antibacterial activity of the formulation was determined by measuring the zone of inhibition.

(i) Adsorption Efficiency

About 2 ml of the formulation was taken in an eppendorf tube and centrifuged at 13000 rpm for 15 min at 4° and 1 ml of the supernatant was collected, diluted with water and the absorbance was measured in UV spectrophotometer at 220 nm wavelength. The amount of drug adsorbed and adsorption efficiency was calculated according to the formula given below.

Amount of drug adsorbed = Initial drug loaded - unadsorbed drug

Adsorption efficiency (%) = [Amount of drug adsorbed/ Initial drug loaded] × 100

(ii) In-vitro drug release studies

Accurately 2 ml of the AgNP liquid formulation was taken in a dialysis bag and closed on both the sides with Hi-media closure clips to prevent the leakage of formulations. Then the dialysis bag was placed inside a beaker containing 50 ml phosphate buffer pH 7.4 and pH 5.8 at room temperature and allowed to stir gently at 100 rpm using magnetic stirrer. Samples were withdrawn at a periodic time intervals from [1-7 hr] and replaced with equal volume of buffer, then the sample was analysed in UV at 220 nm after making suitable dilutions and the absorbance was determined.

(iii) Particle size and Zeta potential analysis for synthesized AgNP

The mean diameter and zeta potential of the samples were measured by Dynamic light scattering (DLS) using zetasizer (Nano ZS 90, Malvern Instruments, United Kingdom). The synthesized AgNP formulations was measured in disposable polystyrene cuvettes at 25°C with a detection angle of 90°. The particle size, Polydispersivity index (PDI) and zeta potential were determined.
(iv) Morphological analysis
Transmission Electron Microscopy (TEM 200 Kv; T12 Fei, TeenaG2 Spirit TWIN) was performed to analyze the surface morphology of AgNP formulations. The sample was placed in a copper grid and kept for air drying at room temperature. The dried sample in the grid was placed till the loading point and scanned under 200 Kv, then the beam was allowed to pass through the sample and the images were scanned under microscope at different nanometer scales.

The prepared slides were coated on the surface of the cover slip and air-dried at 28ºC in room for 12 hr and subjected to AFM analysis. The shape of silver nanoparticles was analyzed using an atomic force microscopy (AFM).

(v) Zone of Inhibition test for determining antibacterial activity of mupirocin loaded AgNP against Staphylococcus aureus

Preparation of Mueller- Hinton (MH) agar plates
Mueller- Hinton (MH) agar medium was prepared according to the manufacturer’s instructions and autoclaved for 20 min at 120 PSI. After autoclaving, the agar medium was cooled to 40-45º in a water bath. The cooled agar medium was poured into a petridish and allowed it to cool further at room temperature.

Agar well diffusion assay
To inoculate the MH agar plates, a sterile cotton swab was dipped into the bacterial suspension and swabbed over the surface of the agar plates. This procedure was repeated over three times, each time the plate was rotated approximately 60º to ensure an even distribution of inoculums. Then a hole was punched aseptically with the help of sterile cork borer with a diameter of 6 to 8 mm with the sterile cork borer and a volume of 20-100 µl of the antimicrobial agent/ AgNP formulations at desired concentration was introduced into the well. Amoxicillin (10µg) was used as positive control. Then the bacterial petridishes were incubated at 37º for 24 hr. The sensitivity of the test organism to each antimicrobial was indicated by clear zone of inhibition around the disc and the diameter of the zone of inhibition was measured.

RESULTS AND DISCUSSION
Preformulation studies
The Melting point was determined as a part of preformulation study since it can affect the absorption of the dosage form12 and was found to be 79ºC which complies with Indian Pharmacopoeia. From the UV-Visible spectrum lambda max of the mupirocin was optimized as 220nm. From the standard graph, absorbance was measured and linearity were obtained between 2-20 µg/ml concentration in mupirocin and the regression value was found to be $r^2 = 0.9896$. (Figure 1)

Particle size and Zeta potential analysis
Particle size of AgNP with NaBH₄ as reducing agent has the particle size distribution between 113nm to 243nm with PDI between 0.3 to 0.5 indicating the homogeneity of the formulation. Zeta potential was found to be between -19mV to -25 mV revealing the presence of a compact surface layer of NaBH₄ on the colloidal silver. The zeta potential of the system should be between -30 to +30 mV to resist aggregation of nanoparticles.

Particle size of AgNP with TSC TA as reducing agent has the particle size distribution between 87 nm to 196 nm which is in accordance with the work done by katarzyna et al., using same procedure of reducing silver nitrate with tannic acid13 with PDI between 0.2 to 0.5 indicating the homogeneity of the formulation. Zeta potential was found to be between -33 mV to -27 mV revealing the presence of a compact surface layer of TSC on the colloidal silver.

Particle size of AgNP with PASA as reducing agent has the particle size distribution between 140 nm to 204 nm which was larger than that is reported by Dian susanthiy et al. synthesized AgNP using PASA14 even though the pH was 11 and the reaction time 20 min. PDI between 0.3 to 0.5 indicating the homogeneity of the formulation. Zeta potential was found to be between -22mV to -25mV. The pH of PASA solution and reaction time has a huge impact on stability of silver nanoparticles by altering the sedimentation rate. Increasing the pH of PASA might increase the reducing property but increases the particle size and decreases the stabilizing performance due to sedimentation of silver ions on storage.15 Hence in this study we have chosen the optimized AgNP formulation

Figure 1: Standard graph of Mupirocin.
reduced with PASA at pH 11 with the reaction time of 20 min which resulted in good stability for 3 months. Particle size of AgNP with ASC which is a weak reducing agent has the particle size distribution between 160 nm to 250 nm with PDI between 0.4 to 0.5 indicating the homogeneity of the formulation. Zeta potential was found to be between -33 mV to -15 mV.

The solution will turn to brighter yellow/brownish red when all of the silver nitrates had been added which is shown in Figure 2. The formulation with the lowest particle size and more stable zeta potential is mentioned in the table given below (Table 1).

Among the different formulation with different reducing agents AgNP-TSC-TA was able to produce the particles with smaller size 87.45 nm indicating it may improve its contact with the skin due to its smaller particle size which may provide synergistic antibacterial activity. The average particle size of AgNP (NaBH₄), AgNP (TSC-TA), AgNP (PASA) and AgNP (ASC) were compared to each other and it is found to have significant p value (p<0.001). A change in the surface potential was observed after the addition of Mupirocin to AgNP. The formulation with the lowest particle size has been selected for further studies.

The resonance wavelength of AgNP formulations in UV depends on the particle size and shape. If the particle size becomes larger the plasmon peak shifts to the longer wavelength and broadens (Table 2). Thus, surface adsorption of silver nanoparticles with Mupirocin did not produce color change and caused broadening of UV spectrum peak except AgNP with ascorbic acid as it produced a marked color change and sedimentation of particles (Figure 3) indicating that ascorbic acid is a weak reducing agent (i.e., it cannot form silver oxide on the surface to retain its color due to the particle size of Mupirocin) thereby causing multiple peaks between 300 to 800 nm.

**Surface adsorption Efficiency**

Adsorption efficiency of mupirocin loaded AgNP (NaBH₄), AgNP (TSC-TA) and AgNP (PASA) formulations after surface adsorption of the drug was found to be 90.5%, 93.5% and 89.5% (Table 3) and there was no color change observed in the formulation after drug adsorption. The maximum entrapment of drug on AgNP TSC TA formulation may be due to higher concentration of TA which may help to hold the drug on its surface.

**In vitro drug release studies**

The in vitro drug release studies was carried out in two different pH (i.e., 5.8 and 7.4) to check the release of the drug at highly regulated pH environment of skin and with the biofilm pH. There was a burst release of Mupirocin at the first hour and the release was extended till the end of 7th h (Table 4). The in-vitro release in AgNP (NaBH₄), AgNP (TSC-TA) and AgNP (PASA) formulations were statistically compared at pH 5.8 and pH 7.4 through one way anova (Figure 4) and the significant p value < 0.005 was observed.

**Morphological analysis (TEM and AFM)**

Surface morphology of AgNP formulation was carried out in TEM micrograph (Figure 5) shows that the formulations are roughly spherical in shape. The size of the particles was calculated by the TEM analysis, which are mainly in range between 100–150 nm which confirms the report given by Dynamic Light Scattering (zeta sizer). Our TEM results are similar to the results of Rita La Spina et al. who reported the particle shape and size of AgNPs as monodispersed spherical nanoparticles.

---

**Table 1: Particle size, Poly dispersity Index and Zeta Potential Characterization of AgNP.**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Particle Size(nm) Nanometer</th>
<th>PDI</th>
<th>Zeta Potential(mV) millivolt</th>
</tr>
</thead>
<tbody>
<tr>
<td>F₁,(3 mg of NaBH₄)</td>
<td>113.3 ± 0.665</td>
<td>0.362 ± 0.011</td>
<td>-25 ± 0.456</td>
</tr>
<tr>
<td>F₂,(24 µM of TA)</td>
<td>87.45 ± 0.94</td>
<td>0.240 ± 0.021</td>
<td>-33.41 ± 0.521</td>
</tr>
<tr>
<td>F₃,(pH 10) of PASA</td>
<td>148.2 ± 0.742</td>
<td>0.398 ± 0.020</td>
<td>-23.6 ± 0.550</td>
</tr>
<tr>
<td>F₄,(7 mg of ASC)</td>
<td>161.9 ± 0.843</td>
<td>0.428 ± 0.023</td>
<td>-33.1 ± 0.429</td>
</tr>
</tbody>
</table>

Data was expressed as mean ± SD (n=3); p<0.005 indicating statistical difference in the particle size between three formulations.

**Table 2: UV spectrum characterization of AgNP.**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Wavelength(nm) nanometer</th>
<th>Before adsorption</th>
<th>After adsorption</th>
</tr>
</thead>
<tbody>
<tr>
<td>AgNP (TSC-TA) + MUP</td>
<td></td>
<td>420</td>
<td>450</td>
</tr>
<tr>
<td>AgNP (NaBH₄) + MUP</td>
<td></td>
<td>410</td>
<td>415</td>
</tr>
<tr>
<td>AgNP (PASA)+MUP</td>
<td></td>
<td>415</td>
<td>430</td>
</tr>
</tbody>
</table>

AgNP - Silver nanoparticle
TA - Tannic acid
PASA - Para amino salicylic acid
ASC - Ascorbic acid
nm - Nano meter
mV - millivolt
Enhanced Antibacterial activity with Antibiofilm Agents

Statistically significant difference between the antibacterial activity of mupirocin vs tannic acid and para amino salicylic acid were analyzed by one way ANOVA test. Mupirocin has significant \( p < 0.0001 \) antibacterial activity than the other two antimicrobial agents. Statistically significant difference between the antibacterial activity of tannic acid and para amino salicylic acid were analyzed by student T test which concluded that there is no significant \( p > 0.0001 \) difference between the two antibiofilm agents.

Bacterial sensitivity test for the synthesized AgNP formulation was carried out for clinical \( S. \) aureus strain. Mupirocin is more effective against \( S. \) aureus than the other antibiofilm agent (Tannic acid and PASA) when tested alone (Table 5). Among the two antibiofilm agents PASA showed better antimicrobial activity. Inspite of its slow drug release on in vitro studies, AgNP-PASA seems to have more antibacterial activity against \( S. \) aureus.

Table 3: Entrapment efficiency of Mupirocin on AgNP.

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Entrapment efficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>AgNP(NaBH(_4))</td>
<td>90.5%</td>
</tr>
<tr>
<td>AgNP(TSC+TA)</td>
<td>93.5%</td>
</tr>
<tr>
<td>AgNP (PASA)</td>
<td>89.5%</td>
</tr>
</tbody>
</table>

Table 4: In vitro drug release data at the end of seventh hour.

<table>
<thead>
<tr>
<th>S.No</th>
<th>Formulation</th>
<th>pH 5.8</th>
<th>pH 7.4</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>AgNP(NaBH(_4))</td>
<td>85% ± 3.566</td>
<td>87% ± 0.5657</td>
</tr>
<tr>
<td>2.</td>
<td>AgNP(TSC+TA)</td>
<td>90% ± 2.434</td>
<td>89% ± 2.343</td>
</tr>
<tr>
<td>3.</td>
<td>AgNP (PASA)</td>
<td>86% ± 1.434</td>
<td>86% ± 1.456</td>
</tr>
</tbody>
</table>

Data was expressed as mean ± SD (n=3); \( p \leq 0.005 \) indicating statistical difference in the in vitro between three formulations.

\( \text{AgNP - Silver nanoparticle} \)
\( \text{TA - Tannic acid} \)
\( \text{TSC - Trisodium citrate} \)
\( \text{PASA - Para amino salicylic acid} \)

Zone of Inhibition

Bacterial sensitivity test was carried out for clinical \( S. \) aureus strain. Mupirocin is more effective against \( S. \) aureus than the other antibiofilm agent (Tannic acid and PASA) when tested alone (Table 5). Among the two antibiofilm agents PASA showed better antimicrobial activity. Inspite of its slow drug release on in vitro studies, AgNP-PASA seems to have more antibacterial activity against \( S. \) aureus.

Statistically significant difference between the antibacterial activity of mupirocin vs tannic acid and para amino salicylic acid were analyzed by one way ANOVA test. Mupirocin has significant \( p \leq 0.0001 \) antibacterial activity than the other two antimicrobial agents. Statistically significant difference between the antibacterial activity of tannic acid and para amino salicylic acid were analyzed by student T test which concluded that there is no significant \( p > 0.0001 \) difference between the two antibiofilm agents.

Hence this study revealed that Mupirocin loaded silver nanoparticles with antibiofilm agents has good antibacterial activity than mupirocin alone.
In the present work silver nanoparticles were synthesized by chemical reduction method using sodium borohydride, tri sodium citrate tannic acid, Para amino salicylic acid as reducing agents and drug mupirocin was surface adsorbed to the formulation. The particle size was in size range of 50nm – 250nm. The zeta potential was in the range of -15 mV to 50 mV and PDI values ranging from 0.2– 0.7. In vitro drug release using dialysis membrane showed maximum release of 90 % ± 2.343 in AgNP (TSC-TA) formulation at 7 hr with the maximum drug entrapment of 93.75%.

The formulations were tested for antimicrobial activity against *S. aureus* and almost all the combination showed effective and synergistic antimicrobial activity. The best synergistic activity against planktonic *S. aureus* bacteria was shown by AgNP- PASA inspite of its minimal drug release when compared to AgNP (TSC TA). Hence this combination can be subjected for further studies to confirm the eradication against biofilm.

**CONCLUSION**

The formulations were tested for antimicrobial activity against *S. aureus* and almost all the combination showed effective and synergistic antimicrobial activity. The best synergistic activity against planktonic *S. aureus* bacteria was shown by AgNP- PASA inspite of its minimal drug release when compared to AgNP (TSC TA). Hence this combination can be subjected for further studies to confirm the eradication against biofilm.

**ACKNOWLEDGEMENT**

The authors would like to thank Fourrts India Laboratories Pvt Ltd, Chennai for providing the gift samples of mupirocin respectively. We gratefully acknowledge our principal Dr. M. Ramanathan.
M.Pharm, Ph.D., for providing the research facilities throughout this work. We also extend our thanks to our institution PSG College of Pharmacy, Coimbatore for the huge facilities offered for completing of our project. We acknowledge Council of Scientific and Industrial Research, New Delhi for providing major extramural research grant to initiate the preliminary research work (Grant. No: 60(0117)/19/EMR-II). We also acknowledge The Tamil Nadu Dr.M.G.R. Medical University, Chennai, India for providing minor research grant.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ABBREVIATIONS

REFERENCES

PICTORIAL ABSTRACT

• The rapid emergence in bacterial resistance is alarming worldwide, endangering the activity of antibiotics. Hence this research work would provide an alternative approach to conventional antibiotic treatment for infection control by employing novel nanoparticles to combat the resistance through biofilms.

Cite this article: Priyaa SRM, Roselin RB, Arjunan K, Sankar V. Formulation of Mupirocin Adsorbed Silver Nanoparticle with Antibiofilm Agents for Enhancing Antibacterial Activity. Indian J of Pharmaceutical Education and Research. 2022;56(1):50-7.